Navigation Links
AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

, Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center, at Dana-Farber Cancer Institute (DFCI) in Boston, MA and Dr. Kenneth C, Anderson, Chief, Division of Hematologic Neoplasia at DFCI.

Dr. Richardson's clinical research focuses on studying novel therapies for multiple myeloma. He was the lead investigator of the SUMMIT and APEX clinical trials that led to the FDA approval of bortezomib (Velcade(R)) for the treatment of multiple myeloma. More recently, he served as clinical trials core chair of the Multiple Myeloma Research Consortium, completing 5 years of service in the role this year. Dr. Anderson serves as Chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee and chairs the scientific advisory board for the Multiple Myeloma Research Foundation. In addition to playing an integral role in the development and approval of bortezomib (Velcade(R)), Drs. Richardson and Anderson led both preclinical and early phase clinical trials for the immunomodulatory drug lenalidomide (Revlimid(R)), leading to its FDA approval in 2007.

Juergen Engel, Ph.D., President and CEO at AEterna Zentaris stated, "We are very excited with Keryx's initiation of this Phase 3 trial with perifosine, our lead oncology compound. Based on prior positive results, we believe that perifosine could become a novel oral combination treatment of great benefit to patients suffering from multiple myeloma."

About the Phase 3 Trial Design

The Phase 3 trial is a randomized (1:1), double-blind trial comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade(R)) and dexamethasone in approximately 400 patients with relapsed or relapsed/refractory multiple myeloma. Patients will be randomized to bortezomib (Velcade(R)) at 1.3 mg/m2 days 1, 4, 8 and 11 every 21 days in combination with dexamethasone 20 mg on the day of and day after bortezomib (Velcade(R)) treatment, and either pe
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Announces Appointment of New Board Member
2. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
5. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
6. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
7. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
8. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
9. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... endured a hard struggle, and somehow survived where other ... same sites and domain names must face harsher realities ... Today without visibility, on e-commerce, Web sites are simply ... the right match, they only clash into the billions ...
... is leading the blog tools market space, has all the ... founders - husband-and-wife team of Ben and Mena Trott - ... and created Moveable Type, arguably the best and most widely ... company name represents the number of days between their birth ...
... agricultural and lawn care pesticides may cause injury to ... to a study conducted by researchers at ... in the May 2004 issue of Environmental Health ... Environmental Health Sciences, National Institutes of Health. , ,In ...
Cached Biology Technology:The mysteries and the future of Web sites 2The mysteries and the future of Web sites 3The mysteries and the future of Web sites 4Six Apart hits its adolescence 2Six Apart hits its adolescence 3Six Apart hits its adolescence 4Six Apart hits its adolescence 5Infertility linked to lawn chemicals by Marshfield Clinic researcher 2
(Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may be the ... Intelligence reports that the long anticipated floodgates for consumer ... demand for smart phones, tablets, and wearable mobile devices ... 2.5 billion users with nearly 4.8 billion biometric devices ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the travel experience ... borders. Over the past decade, ePassports, biometric readers, and ... process through border control via eGates and Automated Passport ... seaports, and land borders across the globe. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... (UM) Rosenstiel School of Marine & Atmospheric Science Professors Shuyi ... Fellows of the American Meteorological Society (AMS), the nation,s leading ... Dr. Bruce Albrecht, who is a Fellow of the ... Award. The honor of Fellow is given to ...
... announced the 12 projects funded in a fourth ... (PIRE) awards. Many of these projects engage scientists ... energy alternatives, as the need for solutions challenges ... Agency for International Development (USAID) today also announced ...
... Texas at Austin have discovered that the lack of a ... neural tube birth defects in developing embryos. It ... dramatically reduces the incidence of neural tube defects, such as ... birth defects. In some populations, folic acid supplementation has decreased ...
Cached Biology News:Univ. of Miami profs Chen and Soden named Fellows of AMS, Albrecht receives AMS Teaching Award 2Univ. of Miami profs Chen and Soden named Fellows of AMS, Albrecht receives AMS Teaching Award 3NSF Supports GlobalNSF supports global research to advance science and engineering for sustainability 2NSF Supports GlobalNSF supports global research to advance science and engineering for sustainability 3NSF Supports GlobalNSF supports global research to advance science and engineering for sustainability 4NSF Supports GlobalNSF supports global research to advance science and engineering for sustainability 5NSF Supports GlobalNSF supports global research to advance science and engineering for sustainability 6NSF Supports GlobalNSF supports global research to advance science and engineering for sustainability 7NSF Supports GlobalNSF supports global research to advance science and engineering for sustainability 8NSF Supports GlobalNSF supports global research to advance science and engineering for sustainability 9NSF Supports GlobalNSF supports global research to advance science and engineering for sustainability 10NSF Supports GlobalNSF supports global research to advance science and engineering for sustainability 11Lack of key enzyme in the metabolism of folic acid leads to birth defects 2
... multicolor analysis in a modern flow cytometer, ... that are differentially labeled with fluorescent probes. ... typically used for cell labeling are broader ... a flow cytometers filters. Thus, the fluorescence ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... ActiveSight, the leading provider of ... design, offers fragment-based screening services to ... screening involves the binding of drug-like ... crystallized protein drug targets, allowing scientists ...
...
Biology Products: